Lynn Tyler wrote an article in the January issue of AIPLA Biotechnology Committee’s “Biotech Buzz” quarterly e-newsletter. The article discussed Valeant Pharm. N.A. LLC v. Mylan Pharm., Inc., in which the Federal Circuit held that, for venue purposes in Hatch-Waxman cases, an act of infringement occurs only in districts where actions related to the submission of an Abbreviated New Drug Application (ANDA) occur.
RELATED PEOPLE
Partner
Food, Drug and Device Practice Chair
F
317-231-7433
×
Subscribe
Do you want to receive more valuable insights directly in your inbox? Visit our subscription center and let us know what you're interested in learning more about.
View Subscription Center
